Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Industrial Info
Recent research progress in Hepatitis B Drugs and Vaccines
2017-10-27
来源：转载自第三方
27 October 2017
Hepatitis B is caused by hepatitis B virus (HBV), it can not be cured once infected, and may be converted to chronic hepatitis, cirrhosis and liver cancer. In the treatment of chronic hepatitis B, there are two categories, namely, interferon (common interferon, long-acting interferon) and nucleosides (Lamivudine, Adefovir, Entecavir), but these drugs are unable to cure hepatitis B. To overcome hepatitis B, scientists are sparing no effort to study new vaccines and new drugs. Here we will review the recent progress in the field of hepatitis B.
The new hepatitis B vaccine TG1050
TG1050 is an innovative hepatitis B vaccine developed by Transgene, which uses adenovirus vectors to express three hepatitis B virus-specific antigens that directly kill HBV-infected cells or inhibit HBV replication by stimulating the immune response of the patient's T lymphocyte medium. Recently, Transgene released the clinical trial results of TG1050. The data suggest that TG1050 is well tolerated and can induce a strong specific immune response, and that no adverse events are caused by the immune response.
ARB-1467 from Arbutus
Arbutus recently said ARB-1467 has shown excellent results in preclinical and clinical trials. ARB-1467 uses Arbutus proprietary delivery technology—lipid nanoparticle platform, which contains three RNAi trigger factors that target all four HBV transcripts, reducing the levels of all viral antigens, cccDNA and HBV DNA. Recent clinical results in Phase 2 indicated that ARB-1467 can lead to a significant reduction in serum HBsAg levels and is well tolerated without serious adverse events.
New hepatitis B drug combination of Replicor
Recently, the Canadian biotechnology company Replicor announced new research data of combination of hepatitis B drug. The combination includes its own developed REP2139, tenofovir dipivoxil fumarate (TDF) and peg-IFN. The data showed that 80% of the patients were not only functionally controlled during treatment, but remained stable after the treatment. During subsequent follow-up, the liver function of these patients gradually became normal. It is estimated that the number of patients with functional cure will continue to increase.
We hope that more new hepatitis B drugs and vaccines can be developed, to completely cure hepatitis B, and inhibit the spread of hepatitis B, to help people overcome this serious disease..
Related links: Adefovir intermediates
Edited by Suzhou Yacoo Science Co., Ltd.
如果涉及转载授权，请联系我们。
